全球经颅磁刺激设备市场规模（按类型、应用、最终用户、区域范围）预测（至 2025 年）

经颅磁刺激设备的市场规模及预测

2024 年经颅磁刺激设备市场规模为 11.3 亿美元，预计到 2032 年将达到 21.6 亿美元，2026 年至 2032 年的复合年增长率为 8.45%。

经颅磁刺激 (TMS) 是一种利用电磁场刺激大脑神经元的非侵入性医疗技术。此技术需要在头皮上放置磁线圈，产生磁场，并在特定脑区感应出电流。 TMS 主要用于调节神经元活动，目前正因其在多种神经和精神疾病中的治疗潜力而受到广泛研究。

TMS 最显着的应用是治疗重度忧郁症，特别是对药物和心理治疗等传统治疗方法没有反应的患者。

目前，TMS 也正被用于治疗其他疾病，包括焦虑症、创伤后压力症候群 (PTSD) 和慢性疼痛。 TMS 通常在门诊进行，患者需在数週内接受多次治疗。

此外，TMS 也用于研究大脑功能和大脑连接，有助于更好地了解神经系统疾病。

TMS 的未来前景光明，目前正在进行的研究旨在拓展其治疗应用并提高其疗效。此技术的进步有望实现更精准的脑区定位，并根据患者的具体需求制定个人化治疗通讯协定。

预计到 2032 年底，经颅磁刺激设备市场规模将达到 21.6 亿美元，复合年增长率为 8.45%。

全球经颅磁刺激设备市场动态

影响全球经颅磁刺激设备市场的关键市场动态是：

关键市场驱动因素

忧郁症和精神疾病的盛行率不断上升：被诊断患有重度忧郁症和其他精神疾病的患者数量不断增加，这推动了对TMS等有效疗法的需求，尤其是对于那些对传统疗法难以奏效的患者。根据世界卫生组织 (WHO) 的数据，截至2022年，全球约有2.8亿人患有忧郁症。美国国家心理健康研究所 (NIMH) 报告称，2020年估计有2,100万成年人至少经历过一次重度忧郁症发作，占美国成年人口的8.4%。

技术进步：TMS 技术的不断创新，例如更精准的脑区定位以及便携式设备的开发，正在改善治疗效果并拓展 TMS 的应用范围，从而推动市场成长。另一家主要参与者 Brainsway 于 2024 年 1 月推出了用于治疗成人焦虑和忧郁症的 Deep TMS H7 线圈，进一步扩展了其技术的应用范围。

提升认知度和接受度：医疗保健提供者和患者对TMS作为一种非侵入性治疗方案的益处和有效性的认识不断提高，将提高其采用率，从而有助于扩大市场。美国精神医学会 (APA) 于2022年更新了其重度忧郁症治疗指南，建议将TMS作为对至少一种抗忧郁症药物未产生反应的患者的二线治疗方案。

有利的法规环境：美国食品药物管理局 (FDA) 等卫生部门的支持性监管政策和核准将促进TMS设备的商业化和普及，从而推动市场成长。欧洲药品管理局 (EMA) 已更新其2024年TMS医疗设备临床研究指南，简化了欧洲市场新TMS设备的核准流程。

主要挑战

保险覆盖范围有限：TMS 治疗的报销政策薄弱和保险覆盖范围有限阻碍了患者获得治疗和接受治疗，对市场成长构成了挑战。

缺乏意识和培训：患者和医疗保健专业人员缺乏意识，并且需要进行专门培训才能执行 TMS，这限制了其广泛采用和接受。

不同的临床结果：治疗结果各不相同，需要进行更广泛、更长期的临床试验来确定不同患者群体的一致有效性，从而影响 TMS 作为可靠治疗方法的可信度。

监管和核准障碍：新的 TMS 设备和应用的严格监管要求和冗长的核准流程减缓了市场进入和创新，对市场扩张构成挑战。

主要趋势

个人化TMS疗法：神经影像学和人工智慧的发展使得开发针对个别脑模式的个人化TMS通讯协定成为可能，从而提高治疗效果和患者预后。 2024年9月发表在《自然神经科学》上的一项研究表明，与标准通讯协定相比，基于个体脑连接模式的个人化TMS通讯协定可将重度忧郁症的治疗效果提高40%。

与数位健康平台的整合：将TMS疗法融入远端医疗和远端监控等数位健康生态系统，可以提高患者的可近性，并实现更全面的治疗管理。根据美国远端医疗协会 (ATA) 2024年12月的报告，预计到2024年，远端医疗服务与TMS的整合将与前一年同期比较增65%。

拓展新的治疗领域：正在进行的研究和临床试验正在探索TMS在更广泛的疾病领域的应用，包括阿兹海默症、中风復健和成瘾治疗，从而拓宽市场范围和潜在应用。 2024年2月，阿兹海默症症协会报告称，三项评估TMS治疗阿兹海默症的大规模临床试验已进入III期，初步结果显示，轻度至中度病例的认知能力有望得到改善。

我们的报告包含可操作的数据和前瞻性的分析，可协助您制定宣传方案、建立商业计划、组织简报或撰写提案。

目录

第一章 引言

• 市场定义
• 市场区隔
• 调查方法

第二章执行摘要

• 主要发现
• 市场概览
• 市集亮点

第三章市场概述

• 市场规模和成长潜力
• 市场趋势
• 市场驱动因素
• 市场限制
• 市场机会
• 波特五力分析

第四章。颅磁刺激设备市场（按类型）

• 单脉衝经颅磁刺激器
• 重复经颅磁刺激（rTMS）
• Theta 爆发经颅磁刺激 (TBS)

第五章 经颅磁刺激设备市场（依应用）

• 神经精神病学
• 神经病学
• 研究与开发
• 影像学诊断

6. 经颅磁刺激设备市场（依最终用户）

• 医院
• 专科诊所
• 研究所
• 诊断影像中心

第七章区域分析

• 北美洲
• 美国
• 加拿大
• 墨西哥
• 欧洲
• 英国
• 德国
• 法国
• 义大利
• 亚太地区
• 中国
• 日本
• 印度
• 澳洲
• 拉丁美洲
• 巴西
• 阿根廷
• 智利
• 中东和非洲
• 南非
• 沙乌地阿拉伯
• 阿拉伯聯合大公国

第八章市场动态

• 市场驱动因素
• 市场限制
• 市场机会
• COVID-19 市场影响

第九章 竞争态势

• 主要企业
• 市场占有率分析

第十章 公司简介

• BrainsWay
• Magstim
• Nexstim
• Salience
• MagVenture A/S
• Neuronetics
• Axilum Robotics

第十一章 市场展望与机会

• 新兴技术
• 未来市场趋势
• 投资机会

第十二章 附录

• 简称列表
• 来源和参考文献

Transcranial Magnetic Stimulators Market Size And Forecast

Transcranial Magnetic Stimulators Market size was valued at USD 1.13 Billion in 2024 and is projected to reach USD 2.16 Billion by 2032, growing at a CAGR of 8.45% from 2026 to 2032.

Transcranial Magnetic Stimulation (TMS) is a non-invasive medical procedure that uses electromagnetic fields to stimulate nerve cells in the brain. This technique involves placing a magnetic coil against the scalp, which generates a magnetic field that induces electric currents in specific brain areas. TMS is primarily used to modulate neuronal activity and has been widely researched for its therapeutic potential in various neurological and psychiatric conditions.

TMS has been most prominently applied in the treatment of major depressive disorder, especially in patients who do not respond to traditional therapies like medication and psychotherapy.

It is also being explored for treating other conditions such as anxiety disorders, post-traumatic stress disorder (PTSD), and chronic pain. The procedure is typically performed in an outpatient setting, with patients receiving multiple sessions over several weeks.

Additionally, TMS is used in research to study brain function and connectivity, helping to advance our understanding of neurological disorders.

The future scope of TMS is promising, with ongoing research aimed at expanding its therapeutic applications and improving its efficacy. Advances in technology may lead to more precise targeting of brain regions and individualized treatment protocols based on specific patient needs.

Transcranial Magnetic Stimulators Market is estimated to grow at a CAGR of 8.45% & reach US$ 2.16 Bn by the end of 2032

Global Transcranial Magnetic Stimulators Market Dynamics

The key market dynamics that are shaping the global transcranial magnetic stimulators market include:

Key Market Drivers

Increasing Prevalence of Depression and Mental Disorders: The rising number of individuals diagnosed with major depressive disorder and other mental health conditions drives the demand for effective treatments like TMS, particularly for patients resistant to conventional therapies. According to the World Health Organization (WHO), as of 2022, approximately 280 million people worldwide were living with depression. In the United States, the National Institute of Mental Health (NIMH) reported that in 2020, an estimated 21 million adults had at least one major depressive episode, representing 8.4% of all U.S. adults.

Technological Advancements: Continuous innovations in TMS technology, such as more precise targeting of brain areas and the development of portable devices, enhance treatment outcomes and expand the scope of TMS applications, fueling market growth. BrainsWay, another major player, launched its Deep TMS H7 Coil for treating adults with anxious depression in January 2024, expanding the applications of their technology.

Growing Awareness and Acceptance: Increasing awareness among healthcare providers and patients about the benefits and efficacy of TMS as a non-invasive treatment option leads to higher adoption rates, contributing to market expansion. The American Psychiatric Association (APA) updated its treatment guidelines for major depressive disorder in 2022, recommending TMS as a second-line treatment for patients who have not responded to at least one antidepressant medication.

Favorable Regulatory Environment: Supportive regulatory policies and approvals from health authorities, such as the FDA in the United States, facilitate the commercialization and adoption of TMS devices, encouraging market growth. The European Medicines Agency (EMA) issued updated guidelines for the clinical investigation of medical devices for TMS in 2024, streamlining the approval process for new TMS devices in the European market.

Key Challenges:

Limited Insurance Coverage: Insufficient reimbursement policies and limited insurance coverage for TMS treatments hinder patient access and uptake, posing a challenge for market growth.

Lack of Awareness and Training: A deficit in awareness among both patients and healthcare professionals, coupled with a need for specialized training to administer TMS, restricts its widespread implementation and acceptance.

Mixed Clinical Outcomes: Variability in treatment outcomes and the need for more extensive, long-term clinical trials to establish consistent efficacy across different patient populations can affect confidence in TMS as a reliable therapy.

Regulatory and Approval Hurdles: Stringent regulatory requirements and the lengthy approval process for new TMS devices and applications can delay market entry and innovation, challenging market expansion.

Key Trends

Personalized TMS Treatments: Advances in neuroimaging and AI are enabling the development of personalized TMS protocols tailored to individual brain patterns, improving treatment efficacy and patient outcomes. According to a study published in Nature Neuroscience in September 2024, personalized TMS protocols based on individual brain connectivity patterns showed a 40% improvement in treatment outcomes for major depressive disorder compared to standard protocols.

Integration with Digital Health Platforms: The incorporation of TMS therapy into digital health ecosystems, including telemedicine and remote monitoring, enhances patient accessibility and allows for more comprehensive treatment management. A report by the American Telemedicine Association (ATA) in December 2024 indicated that the integration of TMS with telemedicine services increased by 65% in 2024 compared to the previous year.

Expansion into New Therapeutic Areas: Ongoing research and clinical trials are exploring the use of TMS for a wider range of conditions, such as Alzheimer's disease, stroke rehabilitation, and addiction, broadening the market's scope and potential applications. The Alzheimer's Association reported in February 2024 that three large-scale clinical trials evaluating TMS for Alzheimer's disease were in phase III, with preliminary results showing promising cognitive improvements in mild to moderate cases.

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Transcranial Magnetic Stimulators Market Regional Analysis

Here is a more detailed regional analysis of the global transcranial magnetic stimulators market:

North America

North America is dominating the transcranial magnetic stimulators (TMS) market owing to the high prevalence of depression and other mental health disorders, advanced healthcare infrastructure, and strong regulatory support. The U.S. TMS market was valued at USD 400 Million in 2024 and was projected to grow at a CAGR of 8.5% from 2024 to 2032, according to data from the Medical Device Manufacturers Association (MDMA) released in March 2024.

The United States, in particular, has a large number of TMS service providers and ongoing clinical research, which contribute to market growth. The region benefits from favorable reimbursement policies and the widespread adoption of new medical technologies. The Anxiety and Depression Association of America (ADAA) stated in February 2024 that approximately 40% of patients with major depressive disorder in the U.S. were considered treatment-resistant, making them potential candidates for TMS therapy.

Asia Pacific

The Asia-Pacific region is experiencing rapid growth in the TMS market due to rising healthcare investments, expanding mental health awareness, and increasing prevalence of neurological disorders. According to a report by the Asia Pacific Medical Technology Association (APACMed) released in February 2024, the TMS market in the Asia-Pacific region was valued at USD 180 Million in 2024 and was projected to grow at a CAGR of 12.5% from 2024 to 2032.

Countries such as China, Japan, and South Korea are at the forefront of this growth, with improving healthcare infrastructure and growing adoption of advanced medical treatments. The China Medical Device Industry Association reported in December 2024 that the Chinese TMS market grew by 18% in 2024 compared to the previous year.

The region's large population base and increasing disposable income also contribute to market expansion. The Japanese Ministry of Health, Labour and Welfare announced in March 2024 a 15% increase in budget allocation for mental health services, including support for TMS treatment centers.

Global Transcranial Magnetic Stimulators Market: Segmentation Analysis

The Global Transcranial Magnetic Stimulators Market is Segmented on the basis of Type, Application, End-User, and Geography.

Transcranial Magnetic Stimulators Market Segmentation Analysis

Transcranial Magnetic Stimulators Market, By Type

• Single Pulse Transcranial Magnetic Stimulators
• Repetitive Transcranial Magnetic Stimulators (rTMS)
• Theta Burst Transcranial Magnetic Stimulators (TBS)

Based on Type, the Global Transcranial Magnetic Stimulators Market is bifurcated into Single Pulse Transcranial Magnetic Stimulators, Repetitive Transcranial Magnetic Stimulators (rTMS), and Theta Burst Transcranial Magnetic Stimulators (TBS). Repetitive transcranial magnetic stimulators (rTMS) currently dominate the transcranial magnetic stimulators market due to their widespread use in treating major depressive disorder and other psychiatric conditions. rTMS is well-established, with extensive clinical evidence supporting its efficacy, making it the preferred choice for many practitioners. Theta burst transcranial magnetic stimulators (TBS) are rapidly growing in popularity as the second-leading segment, driven by their shorter treatment times and emerging research indicating comparable or superior effectiveness to traditional rTMS, thus appealing to both patients and healthcare providers seeking efficient treatment options.

Transcranial Magnetic Stimulators Market, By Application

• Neuropsychiatry
• Neurology
• Research and Development
• Diagnostic Imaging

Based on Application, the Global Transcranial Magnetic Stimulators Market is bifurcated into Neuropsychiatry, Neurology, Research and Development, and Diagnostic Imaging. Neuropsychiatry is the dominating segment in the transcranial magnetic stimulators market, primarily due to the widespread adoption of TMS for treating major depressive disorder, treatment-resistant depression, and other psychiatric conditions. This application has gained significant traction due to strong clinical evidence and growing acceptance in the medical community. Neurology is the second rapidly growing segment, fueled by increasing research and clinical trials exploring the use of TMS for various neurological conditions such as stroke rehabilitation, Parkinson's disease, and chronic pain, expanding the potential therapeutic applications of TMS beyond mental health.

Transcranial Magnetic Stimulators Market, By End-User

• Hospitals
• Specialty Clinics
• Research Institutes
• Diagnostic Imaging Centers

Based on End-User, the Global Transcranial Magnetic Stimulators Market is bifurcated into Hospitals, Specialty Clinics, Research Institutes, and Diagnostic Imaging Centers. Hospitals dominate the transcranial magnetic stimulators market as the primary end-users, leveraging their advanced infrastructure, broad patient base, and comprehensive medical services to provide TMS treatments, particularly for psychiatric and neurological disorders. Specialty Clinics are the second rapidly growing segment, driven by their focused expertise, personalized care, and increasing adoption of TMS for mental health treatments, making them a preferred choice for patients seeking specialized and accessible treatment options.

Transcranial Magnetic Stimulators Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on Geography, the Global Transcranial Magnetic Stimulators Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. North America dominates the transcranial magnetic stimulators market due to its advanced healthcare infrastructure, high prevalence of mental health disorders, and strong regulatory support, particularly in the United States. Europe follows as the second rapidly growing segment, driven by increasing mental health awareness, supportive healthcare policies, and significant investments in mental health services, with key countries like Germany, the United Kingdom, and France leading the adoption of TMS technology.

Key Players

The "Global Transcranial Magnetic Stimulators Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are BrainsWay, Magstim, Nexstim, Salience, MagVenture A/S, Neuronetics, Axilum Robotics.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global Transcranial Magnetic Stimulators Market Key Developments

• In March 2024, Neuronetics, Inc. received FDA clearance for its NeuroStar Advanced Therapy system, incorporating new software algorithms aimed at improving treatment outcomes for depression. This clearance is expected to boost the company's market share and drive adoption rates.
• In June 2024, BrainsWay Ltd. announced the successful completion of a Phase III clinical trial for its Deep TMS (dTMS) device targeting obsessive-compulsive disorder (OCD). This development is anticipated to broaden the application of dTMS and increase market penetration.
• In August 2024, Ybrain Inc. launched a new portable TMS device designed for home use. This innovation aims to make TMS therapy more accessible to patients and reduce the need for frequent clinic visits.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Transcranial Magnetic Stimulators Market, By Type

• Single Pulse Transcranial Magnetic Stimulators
• Repetitive Transcranial Magnetic Stimulators (rTMS)
• Theta Burst Transcranial Magnetic Stimulators (TBS)

5. Transcranial Magnetic Stimulators Market, By Application

• Neuropsychiatry
• Neurology
• Research and Development
• Diagnostic Imaging

6. Transcranial Magnetic Stimulators Market, By End-User

• Hospitals
• Specialty Clinics
• Research Institutes
• Diagnostic Imaging Centers

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• BrainsWay
• Magstim
• Nexstim
• Salience
• MagVenture A/S
• Neuronetics
• Axilum Robotics

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References